Kyverna Therapeutics/$KYTX
1D1W1MYTD1Y5YMAX
Capital at risk
About Kyverna Therapeutics
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
- Ticker
- $KYTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 149
- Headquarters
- EmeryVille, United States
- Website
- kyvernatx.com
KYTX Metrics
BasicAdvanced
$441M
-
-$2.88
1.94
-
Price and volume
Market cap
$441M
Beta
1.94
52-week high
$13.67
52-week low
$5.13
Average daily volume
732K
Financial strength
Current ratio
9.058
Quick ratio
8.746
Long term debt to equity
0.19
Total debt to equity
0.199
Interest coverage (TTM)
-88.69%
Profitability
EBITDA (TTM)
-157.364
Management effectiveness
Return on assets (TTM)
-44.51%
Return on equity (TTM)
-87.24%
Valuation
Price to book
2.65
Price to tangible book (TTM)
2.65
Price to free cash flow (TTM)
-2.358
Free cash flow yield (TTM)
-42.41%
Free cash flow per share (TTM)
-3.024
Growth
Earnings per share change (TTM)
-21.53%
What the Analysts think about KYTX
Analyst ratings (Buy, Hold, Sell) for Kyverna Therapeutics stock.
Analyst projections of the future price of Kyverna Therapeutics stock.
Bulls say / Bears say
FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS), increasing opportunities for priority and rolling reviews to accelerate development. (GlobeNewswire)
Miv-cel remains on track to complete rolling BLA submission in stiff person syndrome (SPS) by Q4 2026, maintaining regulatory momentum toward first-in-class approval. (GlobeNewswire)
As of June 30, 2026, Kyverna held $199.4 million in cash, cash equivalents, and marketable securities, providing operational runway into 2028. (GlobeNewswire)
Kyverna reported a net loss of $38.3 million in Q2 2026, underscoring sustained high cash burn with no profitability to offset expenses. (GlobeNewswire)
Cash reserves declined by approximately $37 million from $236.4 million on March 31 to $199.4 million on June 30, reflecting significant quarterly cash burn and potential pressure on funding. (SEC)
Key pipeline reading milestones remain distant, with KYSA-8 12-month topline data not expected until Q3 2026, delaying material catalysts. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 24 Aug 2026.
KYTX Financial Performance
Revenues and expenses
KYTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing KYTX
AllUSDGBPEUR
Fund name | Fund size | $KYTX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.